• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by EVP - Risk Management Services Bertels Mark E.

    5/19/25 5:50:46 PM ET
    $CRVL
    Specialty Insurers
    Finance
    Get the next $CRVL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bertels Mark E.

    (Last) (First) (Middle)
    5128 APACHE PLUME ROAD, SUITE 400

    (Street)
    FORT WORTH TX 75109

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CORVEL CORP [ CRVL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP - Risk Management Services
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Non-Qualified Stock Option (right to buy) $110.03 05/15/2025 A 2,000 (1) 05/15/2030 Common Stock 2,000 $0.0 2,000 D
    Explanation of Responses:
    1. Exercisable as to 25% of shares one year following grant date with the remaining shares exercisable in 36 equal monthly installments thereafter.
    By: Sharon O'Connor For: Mark Bertels 05/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRVL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CRVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vice President of Accounting Yoss Jennifer

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 7:02:08 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Chief Information Officer Shishin Maxim

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 6:30:11 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Chief Information Officer Shishin Maxim

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 6:27:44 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • CorVel Earns 2025 Great Place To Work Certification™

      FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ:CRVL) is proud to be Certified™ by Great Place To Work® for the fifth year in a row. The prestigious award is based entirely on what current employees say about their experience working at CorVel. Great Place To Work® is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation. "We are very pleased to be recognized as a Great Place To Work for a 5th consecutive year. CorVel is committed to being an organization where people can learn, grow, and advance, and we are grateful for the team members

      2/25/25 7:05:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Corporation Appoints Sarah Scott as Executive Vice President of Product

      FORT WORTH, Texas, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ: CRVL), a national provider of risk management solutions, today announced the promotion of Sarah Scott to Executive Vice President of Product. In her expanded role, Sarah will be responsible for defining and driving the overall product vision and strategy, from ideation to launch and ongoing optimization. Sarah's leadership will ensure the company continues to deliver innovative solutions that create value and meet the evolving needs of its partners. Throughout her 25 years with CorVel, Sarah has been instrumental in the company's success. In her previous role as Vice President of Network Solutions, Sarah playe

      2/13/25 7:25:00 AM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/14/24 6:45:55 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 5:02:29 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 4:05:36 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    SEC Filings

    See more
    • SEC Form 144 filed by CorVel Corp.

      144 - CORVEL CORP (0000874866) (Subject)

      2/11/25 5:22:53 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 10-Q filed by CorVel Corp.

      10-Q - CORVEL CORP (0000874866) (Filer)

      2/6/25 4:30:25 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 144 filed by CorVel Corp.

      144 - CORVEL CORP (0000874866) (Subject)

      2/6/25 4:28:31 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $CRVL
    Leadership Updates

    Live Leadership Updates

    See more
    • CorVel Corporation Appoints Sarah Scott as Executive Vice President of Product

      FORT WORTH, Texas, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ: CRVL), a national provider of risk management solutions, today announced the promotion of Sarah Scott to Executive Vice President of Product. In her expanded role, Sarah will be responsible for defining and driving the overall product vision and strategy, from ideation to launch and ongoing optimization. Sarah's leadership will ensure the company continues to deliver innovative solutions that create value and meet the evolving needs of its partners. Throughout her 25 years with CorVel, Sarah has been instrumental in the company's success. In her previous role as Vice President of Network Solutions, Sarah playe

      2/13/25 7:25:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Announces Retirement of V. Gordon Clemons

      FORT WORTH, Texas, Nov. 29, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ:CRVL) announces V. Gordon Clemons is electing to retire as a member of the Company's Board of Directors (the "Board") and as Chairman of the Board, effective November 26, 2024, after 37 years of service. Clemons founded CorVel Corporation in 1988 and has served as Chairman of the Board since the Company went public in 1991. Effective upon Clemons' retirement, Michael G. Combs, the Company's President and Chief Executive Officer, was appointed as the new Chairman of the Board. Clemons has been an advisor to Combs since 2017, and he will continue to be available to Combs as an outside consultant. "Building CorVe

      11/29/24 1:30:00 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Appoints Jeff Gurtcheff Vice President of Enterprise Comp

      FORT WORTH, Texas , Feb. 02, 2022 (GLOBE NEWSWIRE) -- CorVel, a national provider of risk management solutions, has named Jeff Gurtcheff as Vice President of Enterprise Comp. With more than 30 years of experience, Gurtcheff brings a deep understanding of the industry with strategic leadership and management expertise. As Vice President of Enterprise Comp, Gurtcheff will refine product vision and strategy related to corporate goals and manage resources responsible for regulatory compliance, claims handling, quality, and standards and procedures. His position will also support product line profit growth by developing improved processes, risk management practices, and analytical reporting.

      2/2/22 7:08:00 AM ET
      $CRVL
      Specialty Insurers
      Finance